Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease

Who May Qualify: - Pediatric patients aged between 3 and 20.9 years. - Children diagnosed with sickle cell Anemia (HB SS or HBSB0 Thalassemia) - For the MRD HCT group, children who are candidates for matched related donor hematopoietic stem cell transplantation (MRD HCT). - For the NT-DMT group, children who are receiving non-transplant disease-modifying therapies (NT-DMT) for SCD. - Participants (or their guardians) must provide willing to sign a consent form to be part of the study. - Participants must be willing to undergo the necessary assessments and follow-up visits over the 3-year study period. Who Should NOT Join This Trial: - Children younger than 3 years or older than 20.9 years. - Children who do not have sickle cell anemia or related conditions. - For the MRD HCT group, children who are not eligible for the transplant or do not have a matched related donor. - Children who are currently enrolled in other clinical trials that might interfere with the WeDecide study. - Children who are unable to adhere to the study protocol or follow-up requirements. Always talk to your doctor about whether this trial is right for you.